Dr. Reddy’s Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

Hyderabad, August 22, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Versavo^® (bevacizumab), a biosimilar of Roche’s Avastin^® in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).

Dr. Reddy’s Versavo^® is available in strengths of 100mg and 400mg single use vials.

Commenting on the launch, MV Ramana, CEO – India and Emerging Markets, Dr. Reddy’s Laboratories, said, “We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the medicines they need. The launch of Versavo^® is another step in that journey and helps strengthen our Oncology portfolio.”

Dr. Raymond  De Vré, Global Head, Biologics, Dr. Reddy’s Laboratories added “Versavo^® will help improve access to high quality therapy at an affordable cost, addressing the needs of patients with different cancers in India.”

Avastin^® and its biosimilars had India sales of approximately INR 223 Crore MAT for the most recent twelve months ending in December 2018, according to Ipsos*.

Dr. Reddy’s now has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.

*Ipsos India Tandem Oncology Monitor 2018

Corporate Comm India (CCI Newswire)